Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GlaxoSmithKline Performance Share Plan, specifically regarding notional interest increases following dividend reinvestments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan notifications and does not contain consolidated financial statements or operational metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only changes noted are administrative updates to the notional share holdings of specific directors due to dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Notification of increased notional interests in Ordinary shares for the GlaxoSmithKline Performance Share Plan.
- Participants: Mr. S Dingemans is the only director listed with specific transaction details.
- Transaction Dates and Values:
- July 7, 2011: 2,296.026 shares at a price of 1366.50p.
- October 6, 2011: 2,325.462 shares at a price of 1365p.
- Payout Condition: Notional dividends will be paid out proportionally based on the percentage of holdings that vest after the relevant three-year measurement period.
- Signatory: Victoria Whyte, Company Secretary, signed the report on October 13, 2011.